NCT02398526View on ClinicalTrials.gov

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

CompletedOBSERVATIONAL
Enrollment

363

Participants

Timeline

Start Date

March 19, 2015

Primary Completion Date

May 20, 2020

Study Completion Date

July 15, 2020

Conditions
Castration-Resistant Prostatic Cancer
Interventions
DRUG

Radium-223 dichloride, (Xofigo, BAY88-8223)

Dosage and treatment duration according to the decision of the treating physician

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY